Pulsenmore (PLSM.TA) Action Cours

Pulsenmore Ltd. generates revenue through the sale of its two miniaturized ultrasound systems, PulseNmore ES and PulseNmore FC, designed for home use in remote clinical diagnosis. The PulseNmore ES targets pregnant women requiring regular ultrasound monitoring, while PulseNmore FC caters to women undergoing in vitro fertilization needing follicle size assessments. Both systems integrate with smartphones, enabling patients to conduct tests at home and share results online with healthcare providers. The company also monetizes through software delivery for its devices, enhancing user experience and data management. The primary buyers of PulseNmore ES are pregnant women seeking convenient, clinic-free monitoring, and healthcare providers managing prenatal care remotely. PulseNmore FC is purchased by women undergoing in vitro fertilization, often through fertility clinics or medical centers that recommend the device. These segments value the convenience of home-based diagnostics and seamless telehealth integration without requiring in-person visits. Pulsenmore Ltd. focuses on global markets for its portable ultrasound solutions, serving patients in remote or underserved areas who benefit from telehealth-enabled diagnostics. The company’s products are positioned as cost-effective alternatives to traditional clinic visits, appealing to both end-users and healthcare institutions aiming to reduce operational costs while maintaining patient care quality.